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Objectives The purpose of the present study was to test the potential of colchicine, an agent with potent anti-inflammatory
action, to reduce atrial fibrillation (AF) recurrence after pulmonary vein isolation in patients with paroxysmal AF.
Background Proinflammatory processes induced by AF ablation therapy have been implicated in postablation arrhythmia
recurrence.
Methods Patients with paroxysmal AF who received radiofrequency ablation treatment were randomized to a 3-month
course of colchicine 0.5 mg twice daily or placebo. C-reactive protein (CRP) and interleukin (IL)-6 levels were
measured on day 1 and on day 4 of treatment.
Results In the 3-month follow-up, recurrence of AF was observed in 27 (33.5%) of 80 patients of the placebo group ver-
sus 13 (16%) of 81 patients who received colchicine (odds ratio: 0.38, 95% confidence interval: 0.18 to 0.80).
Gastrointestinal side-effects were the most common symptom among patients receiving active treatment. Diar-
rhea was reported in 7 patients in the colchicine group (8.6%) versus 1 in the placebo group (1.3%, p  0.03).
Colchicine led to higher reductions in CRP and IL-6 levels: the median difference of CRP and IL-6 levels between
days 4 and 1 was 0.46 mg/l (interquartile range: 0.78 to 0.08 mg/l) and 0.10 mg/l (0.30 to 0.10 pg/
ml), respectively, in the placebo group versus 1.18 mg/l (2.35 to 0.46 mg/l) and 0.50 pg/ml (1.15 to
0.10 pg/ml) in the colchicine group (p  0.01 for both comparisons).
Conclusions Colchicine is an effective and safe treatment for prevention of early AF recurrences after pulmonary vein isola-
tion in the absence of antiarrhythmic drug treatment. This effect seems to be associated strongly with a signifi-
cant decrease in inflammatory mediators, including IL-6 and CRP. (J Am Coll Cardiol 2012;60:1790–6)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.031Atrial fibrillation (AF) is the most common sustained
arrhythmia and a significant source of morbidity and mor-
tality (1). Radiofrequency ablation of AF, which initially
tried to mimic the surgical interventions of atrial compart-
mentalization (e.g., the Maze-Cox procedure) (2), evolved
after the seminal publication of Haïssaguerre et al. (3) on
the triggering role of pulmonary veins, into essentially a
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accepted July 16, 2012.technique of electrical isolation of the pulmonary veins,
which is the mainstay in current AF ablation therapy (4).
See page 1797
Proinflammatory processes initiated during ablation ther-
apy have been implicated in early AF recurrence (5), and it
has been shown that brief administration of corticosteroids
can reduce immediate AF recurrences after catheter ablation
of AF (6). However, corticosteroids have several unwanted
effects that preclude their mid-term or long-term use in
postablation patients, especially in a population with a
relatively high prevalence of hypertension and coronary and
structural heart disease. Colchicine, however, is an agent
with potent anti-inflammatory action, shown in a substudy
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October 30, 2012:1790–6 Colchicine After AF Ablationof the COPPS (Colchicine for the Prevention of the
Post-pericardiotomy Syndrome) trial to reduce postopera-
tive AF incidence, without serious adverse effects (7).
Colchicine thus can be regarded as an obvious candidate for
prevention of post-ablation AF recurrence.
The purpose of the present study was to examine in a
randomized, double-blind, controlled trial the potential of
colchicine to reduce AF recurrence in a 3-month period
after radiofrequency isolation of the pulmonary veins in
patients with paroxysmal AF.
Methods
Population. This was a double-blind 2-center study. Pa-
tients with paroxysmal AF were included who had at least 2
documented episodes within the previous 12 months (either
self-terminating within 7 days or cardioverted, medically or
electrically, in fewer than 48 h). At least 1 episode should
have been documented under treatment with a class Ic or III
antiarrhythmic drug. Exclusion criteria were: age older than
80 years, active inflammatory or infectious disease or ma-
lignancy, known autoimmune diseases, corticosteroid or
other immunosuppressive or immunomodulatory therapy,
moderate or severe hepatic impairment (Child-Pugh class B
or C), severe renal failure (estimated glomerular filtration
rate 30 ml/min per 1.73 m2), and inability or unwilling-
ess to adhere to standard treatment or to provide consent.
he protocol was approved by the institutional review
oards. All patients provided informed consent.
rocedures. After a run-in period of 2 months, during
hich all antiarrhythmic medication was discontinued and
ther treatment was stabilized, patients underwent AF
blation. Antral pulmonary vein isolation was performed in
ll patients, with additional ablation of the left atrial
sthmus. An irrigated radiofrequency ablation catheter
Thermocool, Biosense Webster, Diamond Bar, California)
as used to perform ablation, with the aid of electroanat-
mical mapping (Carto XP or Carto 3, Biosense Webster).
ulmonary vein potentials were recorded with a circular
apping catheter (Lasso 2515, Biosense Webster) before,
uring, and after antral ablation. The endpoint of the
blation procedure was the entrance block into all pulmo-
ary veins, as well as noninducibility of AF with atrial burst
acing from the proximal coronary sinus (at a cycle length of
60 ms for three 5-s intervals, followed by decremental
acing until a cycle length of 200 ms or the minimal cycle
ength with 1:1 capture). If AF was induced, further
blation lesions were delivered and inducibility testing was
epeated. Additional ablation of complex atrial fractionated
lectrograms or extrapulmonary triggering sites was left at
he discretion of the operator. A waiting period of 20 min
as allowed to affirm absence of re-conduction. All patients
ere anticoagulated adequately during the ablation and
eceived oral anticoagulation for 3 months after the proce-
ure (anticoagulation thereafter was decided on according
o current guidelines).Blood samples were obtained
rom a peripheral vein using stan-
ard venipuncture techniques to
easure interleukin (IL)-6 and
-reactive protein (CRP). Blood
as collected into collection
ubes without anticoagulant and
as centrifuged 30 min after col-
ection (time allowed for clot-
ing) using a centrifuge with an
ntegrated refrigeration system (at 4°C/1000 g for 15 min)
and were kept at 80°C in multiple aliquots until analysis
(each aliquot was thawed and analyzed once, and no aliquots
were refrozen). Blood samples for CRP and IL-6 measure-
ment were obtained immediately after ablation (day 1) and
after 3 days of colchicine treatment (day 4) using commer-
cially available kits (R&D Systems, Minneapolis, Minne-
sota).
Standard transthoracic and transesophageal (to affirm
absence of atrial thrombi) echocardiography was performed
as part of the preablation preparation checklist in all patients
(not more than 3 days before ablation) following standard-
ized in-house protocols. For the purposes of this study,
digitally stored echocardiography studies were reviewed in a
central laboratory and relevant echocardiographic parame-
ters were recorded in the patient case report form.
Study treatments and adverse event monitoring. Patients
were randomized to receive colchicine or placebo for 3
months. Colchicine was administered from day 1 (the day of
the ablation procedure) at a dose of 0.5 mg twice daily. No
antiarrhythmic drugs (class I or III) were allowed during the
3-month study treatment period (nondihydropyridine cal-
cium channel blockers also were not allowed, and beta-
blocking agents were allowed only for the indications of
heart failure and coronary artery disease, if already taken
before inclusion). Monitoring of adverse events focused on
gastrointestinal manifestations, hepatotoxicity, myelotoxic-
ity, myotoxicity, and alopecia. To monitor potential sub-
clinical organ toxicity, complete blood counts and standard
biochemical analyses (glucose, urea, creatinine, liver en-
zymes, creatine kinase, lactate dehydrogenase) were per-
formed at 2, 6, and 12 weeks after the procedure.
Follow-up for AF recurrences. The duration of the
follow-up was 3 months, starting from the day of the ablation
procedure (no blanking period was applied). The main
outcome measure was AF recurrence. Episodes of atrial
flutter or other macro–re-entrant atrial tachycardia
(MRAT) also were considered as recurrences (for the
purpose of simplicity, the term AF recurrence is used). The
patients were followed up with visits on a 2-week basis in a
dedicated arrhythmia outpatient clinic. Any of the following
was considered to be AF recurrence: symptomatic AF (AF
or MRAT of any duration in symptom-triggered electro-
cardiograms at any time during the study), AF or MRAT of
any duration recorded in electrocardiograms obtained dur-
Abbreviations
and Acronyms
AF  atrial fibrillation
CRP  C-reactive protein
IL  interleukin
IQR  interquartile range
MRAT  macro–re-entrant
atrial tachycardiaing patient visits at the arrhythmia clinic, and AF or MRAT
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Colchicine After AF Ablation October 30, 2012:1790–6of at least 30 s duration in 48-h ambulatory electrocardio-
gram recordings (Holter) performed twice monthly (each
patient had 6 48-h Holter recordings during the 3-month
study period). Patients who did not appear for more than 1
visit, for more than 1 Holter recording, or both were
excluded from analysis to avoid underdetection of AF
recurrence.
Statistical analysis. A sample size of 160 (80 in each
randomization group) provided 80% possibility to detect a
50% reduction (1-sided) of early AF recurrence (from 40%
to 20%) at an alpha level of 0.05. Analysis was performed on
an intention-to-treat basis. All patients who received at least
1 dose of study treatment were included (with the exception
of those not adhering to follow-up requirements, as already
described). Continuous variables were expressed as mean 
standard error of the mean and were compared using the t
est, if their distribution did not deviate significantly from
he normal distribution (tested with the Kolmogorov-
mirnov test). If significant deviation from the normal
istribution was found, continuous variables were expressed
s median (interquartile range [IQR]) and were compared
sing nonparametric tests (the Wilcoxon and Mann–
hitney U tests). Categorical variables were expressed as
ercentages and numbers and were compared using the
Patient CharacteristicsTable 1 Patient Characteristics
Feature
Overall
(n  161)
Epidemiological background
Age (yrs) 62.0 6.0
Male 115 (71%)
BMI (kg/m2) 26.0 (24.0–28.5)
Smoking 58 (36%)
Hypertension 61 (38%)
Diabetes 41 (26%)
Coronary artery disease 55 (34%)
Heart failure 39 (24%)
Valvular heart disease 17 (11%)
Echocardiographic and laboratory parameters
LV ejection fraction (%) 55 (45–60)
LA diameter (mm) 43.5 3.2
CRP day 1 (mg/l) 5.3 (4.4–6.7)
CRP day 4 (mg/l) 4.4 (3.3–5.4)
IL-6 day 1 (pg/ml) 3.1 (2.6–3.9)
IL-6 day 4 (pg/ml) 2.7 (2.1–3.4)
Procedure-related parameters
Procedure duration (min) 187.7 39.6
Acute PV isolation success* 158 (98%)
Noninducibility of AF after ablation 146 (91%)
CAFE ablation 84 (52%)
Treatment
Beta-blocker 58 (36%)
ACEi/ARB 87 (54%)
CCB 66 (41%)
Statin 60 (37%)
Values are mean  SD, n (%), or median (interquartile range). *Defined as entrance block into al
ACEi angiotensin converting enzyme inhibitor; ARB angiotensin receptor blocker; AF atrial fibr
channel blocker; CRP  C-reactive protein; IL  interleukin; LA  left atrium; LV  left ventricle; PV  phi-square test. Kaplan-Meier analysis was performed to
ssess recurrence-free survival, and the log-rank test was
sed to make comparisons between groups. Multivariate
nalysis of the association of univariate predictors to AF
ecurrence was performed using Cox regression. The associa-
ion of on-treatment levels of proinflammatory biomarkers
ith the outcome and their interaction with treatment was a
respecified analysis of the study. SPSS software version 17
as used (SPSS, Inc., Chicago, Illinois), and p  0.05
2-sided) was considered to indicate statistical significance.
esults
aseline characteristics and study flow. The patient char-
cteristics are presented in Table 1. The 2 groups were well
alanced, with equivalent epidemiological profile and back-
round features, including rates of heart failure, coronary
rtery disease, and valvular heart disease. Of 210 patients
nitially screened, 170 were randomized (Fig. 1): 85 in the
olchicine group and 85 in the placebo group. Four and 5
atients, respectively, failed to appear for more than 1 visit
r Holter recording and were excluded from analysis.
ain outcome measure. Recurrence of AF was observed
n 27 (33.5%) of 80 patients in the placebo group, compared
Colchicine Group
(n  81)
Placebo Group
(n  80) p Value
62.0 5.9 62.1 6.0 1.00
60 (74%) 55 (69%) 0.46
26.0 (24.0–28.5) 26.0 (24.0–28.8) 0.86
29 (36%) 29 (36%) 0.95
31 (38%) 30 (38%) 0.92
21 (26%) 20 (26%) 0.89
28 (35%) 27 (34%) 0.91
21 (26%) 18 (23%) 0.61
10 (12%) 7 (9%) 0.55
55 (45–60) 55 (45–60) 0.87
43.5 3.2 43.6 3.1 0.76
5.5 (4.4–6.9) 5.2 (4.4–6.4) 0.48
3.6 (3.2–5.0) 4.6 (3.6–5.9) 0.01
3.2 (2.6–4.0) 3.1 (2.6–3.7) 0.47
2.6 (2.0–3.1) 3.0 (2.2–3.5) 0.01
190.8 41.4 184.6 37.8 0.32
79 (98%) 79 (99%) 0.95
72 (89%) 74 (93%) 0.56
41 (51%) 43 (54%) 0.62
32 (38%) 27 (34%) 0.55
45 (56%) 42 (53%) 0.70
33 (41%) 33 (41%) 0.95
29 (36%) 31 (39%) 0.75
nary veins.l pulmo
illation; BMI body mass index; CAFE complex atrial fractionated electrogram; CCB calcium
ulmonary vein.
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October 30, 2012:1790–6 Colchicine After AF Ablationwith 13 (16%) of 81 patients who received colchicine (p 
0.01, odds ratio: 0.38, 95% confidence interval: 0.18 to
0.80). The number needed to treat to prevent 1 case of AF
recurrence was 5.6. The Kaplan-Meier analysis showed a
significant divergence of the cumulative hazard curves for
AF recurrence in the 3 months after the ablation procedure
(p  0.01) (Fig. 2). Mean recurrence-free time was 68.9
days (95% confidence interval: 61.7 to 76.1 days) in the
placebo group versus 82.2 days (95% confidence interval:
77.8 to 86.7 days) with colchicine (all subjects without
events censored at 90 days). If the 9 patients who were
Figure 1 Study Flow Chart
Flow diagram of the study.
Figure 2 Atrial Fibrillation
Recurrence in the 2 Treatment Groups
Kaplan-Meier curves of the cumulative hazard of atrial fibrillation (AF) recur-
rence within 3 months after pulmonary vein isolation according to treatment
randomization.pexcluded from analysis because of failure to appear for more
than 1 visit or Holter recording (Fig. 1) were included (all
were free of AF recurrence), the results would not be altered
significantly (AF recurrence rate: 31.8% in the placebo
group versus 15.3% in the colchicine group, p  0.01,
nivariate odds ratio: 0.39).
esponse of inflammatory markers to treatment. The
edian levels of CRP and IL-6 on day 1 were similar in the
groups, as expected, whereas there was a significant
ifference on day 4, with higher CRP and IL-6 levels in the
lacebo group (Table 1). Colchicine led to a significantly
igher reduction in CRP and IL-6 levels: the median
ifference in CRP and IL-6 levels between days 4 and 1 (day
levels minus day 1 levels) was0.46 mg/l (IQR:0.78 to
0.08 mg/l) and 0.10 pg/ml (IQR: 0.30 to 0.10 pg/ml),
espectively, in the placebo group, compared with 1.18
g/l (IQR: 2.35 to 0.46 mg/l) and 0.50 pg/ml (IQR:
1.15 to 0.10 pg/ml) in the colchicine group (p  0.01
for both comparisons).
Adverse events and treatment discontinuation. Gastro-
intestinal side-effects of colchicine (mainly diarrhea and
nausea) were the most common ones reported, with higher
frequency among patients receiving active treatment com-
pared with those in the placebo group. Diarrhea was
reported in 7 (8.6%) of 81 patients of the colchicine group
versus 1 (1.3%) of 80 in the placebo group (p  0.03). Four
4.9%) patients receiving colchicine reported nausea versus 3
atients (3.8%) receiving placebo (p  0.71). No cases of
lopecia or myelotoxicity were recorded. One case of transam-
nase elevation higher than the upper limit of normal was
eported in the colchicine group, which was reversed com-
letely after interruption of treatment (the patient was
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Colchicine After AF Ablation October 30, 2012:1790–6asymptomatic, without elevation of bilirubin). No serious
adverse events were reported (i.e., fatal or life-threatening
events or those requiring hospitalization or medical inter-
vention). Treatment discontinuation before the end of the
study was reported in 10 (12.3%) patients in the colchicine
group versus 5 (6.3%) patients in the placebo group (p 
0.18). In most of these cases, treatment was administered
for a substantial period: discontinuation before completing
at least 1 month of treatment was reported in only 3 cases in
the colchicine group and 1 in the placebo group.
Predictors of AF recurrence. Patients with recurrence of
AF were older than those without recurrence. They had, as
expected, a larger left atrium, and the prevalence of hyper-
tension among them was more than double that among
patients without recurrence (Table 2). The CRP and IL-6
levels, both immediately after ablation (day 1) and on day 4,
were correlated positively with the probability of AF recur-
rence (Table 2). The AF recurrence rate in the upper
quartile of IL-6 day 4 levels was 57.5% versus 0% in the
lowest quartile (p 0.01) (Fig. 3). The correlation of age to
F recurrence was rather weak, whereas IL-6 levels on day
were the most powerful univariate predictor of recurrence
Fig. 4).
Randomization to active treatment with colchicine re-
ained a significant predictor of freedom from AF recur-
ence after controlling for age, sex, presence of hypertension,
nd left atrial diameter (multivariate p  0.007). The
roportional hazard ratio in the Cox regression analysis was
.40 (95% confidence interval: 0.21 to 0.78) for AF recur-
ence in patients in the colchicine group compared with
hose in the placebo group. Of interest, if IL-6 levels on day
(i.e., on-treatment IL-6) were entered, the overall model
hanged significantly (chi-square change: 36.3, p  0.01),
nd the association of colchicine treatment with the out-
ome was attenuated markedly (the proportional hazard
atio became 0.64, 95% confidence interval: 0.31 to 1.29,
 0.21). In the final equation, the day 4 IL-6 level was a
ignificant independent predictor of AF recurrence (propor-
ional hazard ratio: 5.1 per unit of IL-6 increase, 95%
onfidence interval: 2.9 to 8.9). The same results were
Univariate Predictors ofAtrial Fibrillation RecurrenceTable 2 Univariate Predictors ofAtrial Fibrillation Recurrence
AF Recurrence
(n  40)
No AF Recurrence
(n  121) p Value
Age (yrs) 63.8 0.9 61.4 0.5 0.03
Randomization to active
treatment
13 (33%) 68 (56%) 0.01
Hypertension 26 (65%) 35 (29%) 0.01
LA diameter (mm) 46 (44–48) 42 (40–45) 0.01
CRP day 1 (mg/l) 6.8 (5.5–7.3) 5.1 (4.2–6.0) 0.01
CRP day 4 (mg/l) 5.7 (5.2–6.6) 3.6 (3.2–4.6) 0.01
IL-6 day 1 (pg/ml) 4.0 (3.2–4.2) 3.0 (2.5–3.5) 0.01
IL-6 day 4 (pg/ml) 3.5 (3.1–3.9) 2.4 (2.0–3.0) 0.01
Values are mean  SD, n (%), or median (interquartile range).
Abbreviations as in Table 1.erived if on-treatment CRP levels were added to the modelthe proportional hazard ratio for colchicine treatment
hanged to 0.68, 95% confidence interval: 0.34 to 1.38, p 
.28, when day 4 CRP levels were added to the model). On
he contrary, addition of day 1 (baseline) levels of either
L-6 or CRP did not affect the independent association of
reatment to the outcome. This means that the effect of
olchicine treatment on the occurrence of AF is almost
otally explained, from a statistical point of view, by the
ffect of treatment on the measured proinflammatory
iomarkers.
iscussion
he principal finding of the present study was that colchi-
ine, administered after catheter ablation of AF, is a safe
nd effective medication for prevention of early AF recur-
ence. Colchicine resulted in significant reductions of pro-
nflammatory biomarkers, namely CRP and IL-6, and this
eduction was associated to lower AF recurrence. A rela-
ively low dose was used for this study (0.5 mg twice daily),
hich may account for the excellent tolerability profile
hown during the 3-month treatment, although higher
oses (1 mg twice daily) were used in the COPPS study (7),
ithout any serious adverse events.
Colchicine is believed to act through inhibition of mi-
rotubule assembly in cells of the immune system, particu-
arly neutrophils, leading to inhibition of several cellular
unctions, including cytokine production by these cells (7).
ts method of action includes modulation of chemokine and
rostanoid production and inhibition of neutrophil and
ndothelial cell adhesion molecules (8). On the whole,
olchicine has a potent anti-inflammatory effect, which was
hown in patients who had undergone cardiac surgery to be
ble to prevent postoperative AF (7). The model of post-
perative AF resembles that of early AF recurrence after
atheter ablation, because in both of these clinical scenarios,
Figure 3 AF Recurrence According to
On-Treatment Interleukin 6 Levels
Rate of AF recurrence during the 3-month study period per quartile of on-treat-
ment (day 4) interleukin (IL)-6 levels (p  0.01 for the differences between
quartiles) in the study population (n  161). Abbreviation as in Figure 2.
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October 30, 2012:1790–6 Colchicine After AF Ablationa strong inflammatory activation comes into play (9,10).
After catheter ablation of AF, increased inflammatory
biomarkers are correlated to delivered energy and are asso-
ciated with early recurrence (9). In an early and very
interesting study, McCabe et al. (10) showed that CRP
levels were increased significantly up to 3 months after AF
ablation, as opposed to ablation of supraventricular tachy-
cardia. Further, CRP was associated significantly with AF
recurrence before the first follow-up visit (37 to 93 days after
ablation). This protracted increase of inflammatory markers
after AF ablation constituted the basis for choosing the
treatment period for our study (3 months), although intui-
tively one would think that inflammatory processes after
ablation should recede in a more timely manner. The
persistent effect of acute factors influencing AF recurrence
over the first few weeks after ablation is reflected in recently
published guidelines defining the time frame of early AF
recurrence at 3 months after ablation (4), which coincides
with the blanking period used in several trials of AF catheter
Figure 4 Predictors of Recurrence
Kaplan-Meier curves of the cumulative hazard of AF recurrence according to age (d
left atrial (LA) diameter (dichotomized), and on-treatment (day 4) IL-6 levels (dichoablation (11). Of note, although recurrences during theblanking period are not considered to be treatment failures,
their prognostic value for later AF recurrence is high, as
repeatedly shown in studies involving relatively large num-
bers of patients (12,13). In the 5A (Antiarrhythmics After
Ablation of Atrial Fibrillation) study, lack of early AF
recurrence during the initial 6-week blanking period was the
only predictor of 6-month freedom from AF (14). There-
fore, prevention of early recurrences seems to be a clinically
relevant objective.
Anti-inflammatory treatment as a means of reducing very
early recurrences after AF ablation has been reported in the
past by Koyama et al. (6), who showed that a short course of
corticosteroids indeed was effective in that respect. It is
interesting, however, that in the case of corticosteroids, an
effect was seen only in the first few days after ablation
(designated by the authors as an immediate recurrence),
whereas no difference was observed 4 to 30 days after the
procedure. The difference from the effect of colchicine on
AF recurrence observed in our study may be explained by
mized), presence or absence of hypertension,
d) in the study population (n  161). Abbreviations as in Figures 2 and 3.ichoto
tomizethe different treatment duration. A more prolonged course
1796 Deftereos et al. JACC Vol. 60, No. 18, 2012
Colchicine After AF Ablation October 30, 2012:1790–6of corticosteroid treatment is precluded by their serious
potential side-effects, whereas colchicine seems to be suit-
able for safe midterm administration. Differences of effect
also can be attributed to specific features of the method of
action of these drugs: in addition to neutrophils and other
immune cells, colchicine may affect cardiac myocytes di-
rectly, because microtubules play important roles in ion
transport modulation, adrenergic stimulation, and intercel-
lular interactions (15–17). Functional parameters and bio-
synthesis, localization, activity, and degradation of calcium
and potassium channels have been linked to the polymer-
ization and depolymerization of microtubules (18), whereas
proliferation of microtubules in experimental models of
stretch-induced arrhythmia increased the arrhythmogenic
effect of transient diastolic stretch (19). As a result, colchi-
cine may exert direct effects on the atrial electrical substrate,
in addition to its anti-inflammatory action.
Study limitations. In studies of AF recurrence, there is
always an issue of adequate detection of recurrences, con-
sidering that a large proportion of AF episodes are asymp-
tomatic (4). The negative predictive value of prolonged
Holter recordings is moderate at best (20). However, in the
present study, an intensive follow-up protocol was observed
with a great number of visits and Holter recordings per
patient, aiming at maximizing the efficiency of AF detec-
tion. More importantly, it was the difference in the inci-
dence of AF recurrence between the 2 groups—not the
absolute recurrence rate—that mattered in this study. Con-
sequently, because there is no reason to believe that AF
detection preferentially was more or less efficient in 1 of the
2 treatment arms, the issue of adequate AF detection should
not have influenced in any way the main conclusions of this
study. Another aspect of the present study that would need
clarification, if colchicine was to be used in this context, is
the required length of treatment after AF ablation. We
selected a 3-month treatment period based on past reports
on proinflammatory activation after ablation (10), but it is
nevertheless conceivable that a different duration of treat-
ment also could be effective.
Conclusions
Colchicine is an effective and safe treatment for prevention
of early AF recurrences after radiofrequency pulmonary vein
isolation, in the absence of antiarrhythmic drug treatment.
This effect seems to be associated strongly with a significant
decrease in inflammatory mediators, including IL-6 and
CRP. These results, should they be confirmed, suggest a
role for colchicine in the therapeutic management of pa-
tients undergoing catheter ablation of AF.
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